Slingshot members are tracking this event:

Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process

Additional Information

Additional Relevant Details
The CHMP positive opinion is based on data from the Phase 3 head-to-head ENDEAVOR study in which patients with multiple myeloma treated with Kyprolis plus dexamethasone achieved superior progression-free survival (PFS) of 18.7 months compared to 9.4 months in those receiving Velcade® (bortezomib) plus dexamethasone, (HR=0.53; 95 percent CI: 0.44,0.65 p<0.0001). The most common adverse reactions that occurred in greater than 20 percent of patients in the Kyprolis arm were anemia, fatigue, diarrhea, thrombocytopenia, nausea, pyrexia, dyspnea, respiratory tract infection, cough and peripheral edema.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 27, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Relapsed Multiple Myeloma, Endeavor Study, Velcade, Kyprolis, Bortezomib, Anemia, Fatigue, Diarrhea, Thrombocytopenia, Lenalidomide, Dexamethasone